Markers of increased cardiovascular risk in patients with chronic kidney disease

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Gluba Brzózka, Anna ^a   Michalska Kasiczak, Marta ^a   Franczyk Skóra, Beata ^a   Nocuń, Marek ^b   Banach, Maciej ^a   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Atherosclerosis; CAD risk; Calcification; Chronic kidney disease

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ALBUMIN; BIOCHEMICAL MARKER; CALCIUM ION; CREATININE; FETUIN A; GELATINASE A; GELATINASE B; HEMOGLOBIN; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX GAMMA CARBOXYGLUTAMIC ACID PROTEIN; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; PHOSPHATE; POTASSIUM; RENALASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; UREA; URIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); BIOLOGICAL MARKER; MMP2 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN;

AGED; ALBUMIN BLOOD LEVEL; AORTA VALVE; AORTA VALVE CALCIFICATION; AORTA VALVE DISEASE; ARTICLE; ATHEROSCLEROSIS; CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD; CALCINOSIS; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-2-HS-GLYCOPROTEIN; AORTIC VALVE; BIOLOGICAL MARKERS; CALCINOSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MONOAMINE OXIDASE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84908013136     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-135     Document Type: Article

References (82)

1. Increased ABCA1 activity protects against atherosclerosis. Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart JC, McManus BM, Staels B, Hayden MR, J Clin Invest 2002 110 35 42
2. American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, Circulation 2003 108 2154 2169
3. Clinical epidemiology of cardiovascular disease in chronic renal disease. Foley RN, Parfrey PS, Sarnak MJ, Am J Kidney Dis 1998 32 112 S119
4. AHA statistical update heart disease and stroke statistics-2014 update. A report from the american heart association. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, et al. Circulation 2014 129 28 e292
5. US Renal Data System, 2002 Annual Data Report, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2002
6. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Foley RN, Parfrey PS, Harnett JD, Kidney Int 1995 47 186 192
7. Chronic kidney disease specific cardiovascular risk factors among non dialytic patients with chronic kidney disease stage-V-An experience of a specialized hospital Bangladesh. Saha M, Faroque MO, Alam KS, Alam MM, Ahmed S, Med Res Counc Bull 2012 38 18 22
8. Hemodialysis Study Group, The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration: Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. Rocco MV, Yan G, Gassman J, Lewis JB, Ornt D, Weiss B, Levey AS, Am J Kidney Dis 2002 39 146 153
9. Registro Lombardo Dialisi e Trapianto: cardiovascular disease in chronic renal failure: the challenge continues. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D, Nephrol Dial Transplant 2000 15 Suppl 5 69 80
10. Cardiovascular disease and mortality in a community based cohort with mild renal insufficiency. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D, Kidney Int 1999 56 2214 2219
11. Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Duymelinck C1, Deng JT, Dauwe SE, De Broe ME, Verpooten GA, Kidney Int 1998 54 804
12. Molecular changes in extracellular matrix turnover after renal ischaemia-reperfusion injury. Jain S, Bicknell GR, Nicholson ML, Br J Surg 2000 87 1188
13. Anemia in chronic kidney disease: causes, diagnosis, treatment. Nurko S, Cleve Clin J Med 2006 73 3 289 297
14. The role of Toll-like receptors in renal diseases. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J, Nat Rev Nephrol 2010 6 4 224 235
15. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. Martínez-Castelao A1, Górriz JL, Portolés JM, De Alvaro F, Cases A, Luño J, Navarro-González JF, Montes R, De la Cruz-Troca JJ, Natarajan A, Batlle D, BMC Nephrol 2011 12 53
16. Chronic Kidney Disease, Stages 1-3. A guide to Clinical Practice Luzern, Switzerland: EDTNA/ERCA, Mahon A, Jenkins K, 1 2007
17. An indistinct balance: the safety and efficacy of parenteral iron therapy. Besarab A, Frinak S, Yee J, J Am Soc Nephrol 1999 10 2029 2043
18. Dyslipidemia in chronic kidney disease. Pathogenesis and intervention. Piecha G, Adamczak M, Ritz M, Pol Arch Med Wewn 2009 119 7-8 487 492
19. Lipid and blood pressure meta-analysis collaboration group: a meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Nikolic D, Banach M, Nikfar S, Salari P, Mikhailidis DP, Toth PP, Abdollahi M, Ray KK, Pencina MJ, Malyszko J, Rysz J, Rizzo M, Int J Cardiol 2013 168 6 5437 5447
20. Lipid and blood pressure meta-analysis collaboration group: effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Nikolic D, Nikfar S, Salari P, Rizzo M, Ray KK, Pencina MJ, Mikhailidis DP, Toth PP, Nicholls SJ, Rysz J, Abdollahi M, Banach M, Curr Med Res Opin 2013 29 5 435 451
21. Management of renal bone disease. Roberts DM, Singer RF, Aust Prescr 2010 33 34 37
22. The long-term evolution of uremic cardiomyopathy. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE, Kidney Int 1998 54 1720 1725
23. Left ventricular hypertrophy in the renal patient. Middleton RJ, Parfrey PS, Foley RN, JASN 2001 12 5 1079 1084
24. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS, Kidney Int 2004 65 1492 1498
25. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. London GM1, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME, J Am Soc Nephrol 2001 12 2759 2767
26. Left ventricular diastolic function in a predialysis patient population. Arodiwe EB, Ulasi II, Ijoma CK, Ike SO, West Afr J Med 2010 29 4 225 229
27. Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease. Wang AYM, Wang M, Lam CWK, Chan IHS, Zhang Y, Sanderson JE, Hypertension 2008 52 1 107 114
28. Elevated E/E' predicts cardiovascular events in hemodialysis patients with preserved systolic function. Iwabuchi Y, Ogawa T, Inoue T, Otsuka K, Nitta K, Intern Med 2012 51 2 155 160
29. Aortic stiffness and valvular calcifications in patients with end-stage renal disease. Zapolski T, Wysokinski A, Janicka L, Grzebalska A, Ksiazek A, Pol Arch Med Wewn 2008 118 3 111 118
30. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, Kidney Int 2009 76 suppl 113 1 S130
31. The study of some risk factors of coronary artery calcification in patients on peritoneal dialysis. Janicka L1, Czekajska-Chehab E, Duma D, Grzebalska AM, Mierzicki P, Orłowska-Kowalik G, Solski J, Drop A, Ksiazek A, Pol Arch Med Wewn 2006 4 14 20 in polish
32. Vascular calcification in dialysis patients: Pathogenesis and consequences. Relterowa M, Moe SM, Am J Kidney Dis 2003 41 3 Suppl 1 96 S99
33. Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Musial K, Zwolinska D, Cell Stress Chaperones 2011 16 1 97 103
34. Valvular calcification and its relationship to atherosclerosis in chronic kidney disease. Leskinen Y, Paana T, Saha H, Groundstroem K, Lehtimäki T, Kilpinen S, Huhtala H, Airaksinen J, J Heart Valve Dis 2009 18 4 429 438
35. Association of serum phosphate with vascular and valvular calcification in moderate CKD. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR, JASN 2009 20 2 381 387
36. Remission of renal disease: recounting the challenge, acquiring the goal. Brenner BM, J Clin Invest 2002 110 1753 1758
37. Vascular calcification: the killer of patients with chronic kidney disease. Mizobuchi M, Towler D, Slatopolsky E, J Am Soc Nephrol 2009 20 1453 1464
38. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. London GM, Guerin AP, Marchais S, Metivier F, Pannier B, Adda H, Nephrol Dial Transplant 2003 18 1731 1740
39. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM, Hypertension 2001 38 938 942
40. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE, J Am Soc Nephrol 2003 14 159 168
41. The risk of atherosclerosis in patients with chronic kidney disease. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J, Int Urol Nephrol 2013 45 6 1605 1612
42. Metabolic syndrome and renal disease. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M, Int J Cardiol 2013 5 164(2) 141 150
43. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC, Am J Kid Dis 1996 27 3 394 401
44. Mechanisms of vascular calcification in chronic kidney disease. Moe SM, Chen NX, JASN 2008 19 2 213 216
45. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Wada T1, McKee MD, Steitz S, Giachelli CM, Circ Res 1999 84 166 178
46. Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism? Razzaque MS, Nephrol Dial Transplant 2011 26 1 42 45
47. Effect of renal function on plasma levels of bone Gla-protein. Delmas PD, Wilson DM, Mann KG, Riggs BL, J Clin Endocrinol Metab 1983 57 1028 1030
48. Osteoprotegerin-deficient mice and onset osteoporosis and arterial calcification. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS, Genes Dev 1998 12 1260 1268
49. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Jersmann HP, Dransfield I, Hart SP, Clin Sci 2003 105 273 278
50. Evaluation of serum osteoprotegerin and fetuin A levels in Egyptian patients with chronic kidney disease. Nessim IG, Abd el Wahab A, Madani HA, Waked E, Abd el Khalek A, Mabrouk K, Comp Clin Pathol 2011 20 5 421 425
51. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S, Kidney Int 2005 67 1070 1077
52. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W, J Clin Invest 2003 112 357 366
53. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J, Lancet 2003 361 827 833
54. Association of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, Lui SF, Li PK, Sanderson JE, Nephrol Dial Transplant 2005 20 1676 1685
55. Phosphate regulation of vascular smooth muscle cell calcification. Jono S, McKee MD, Murry CE, Shioi A, Morii HO, Circ Res 2000 87 10 E17
56. Media calcification and intima calcification are distinct entities in chronic kidney disease. Amann K, Clin J Am Soc Nephrol 2008 6 1599 1605
57. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. Zhang J1, Fu M, Myles D, Zhu X, Du J, Cao X, Chen YE, FEBS Lett 2002 521 180 184
58. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nitta K1, Akiba T, Uchida K, Otsubo S, Takei T, Yumura W, Kabaya T, Nihei H, Nephrol Dial Transplant 2004 19 1886 1889
59. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM, J Am Soc Nephrol 2006 17 1 262 270
60. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimbürger O, Bárány P, Alvestrand A, Lindholm B, Suliman ME, Am Soc Nephrol 2006 17 262 270
61. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR, Circulation 2004 110 3480 3487
62. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Rysz J, Banach M, Stolarek RA, Mikhailidis DP, Cialkowska-Rysz A, Pokoca L, Piechota M, Baj Z, Int Urol Nephrol 2011 43 2 491 498
63. Transforming growth factor beta and CD105 expression in calcification and bone formation in human atherosclerotic lesions. Jeziorska M, Z Kardiol 2001 90 Suppl 3 23 26
64. Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease. Nagano M, Fukami K, Yamagishi S, Ueda S, Kaida Y, Matsumoto T, Yoshimura J, Hazama T, Takamiya Y, Kusumoto T, Gohara S, Tanaka H, Adachi H, Okuda S, Am J Nephrol 2008 29 109
65. Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. Chen NX, O'Neill KD, Chen X, Kiattisunthorn K, Gattone VH, Moe SM, Am J Nephrol 2011 34 3 211 219
66. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. Vaughan AM, Oram JF, J Lipid Res 2006 47 2433 2443
67. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. Yvan-Charvet L1, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR, J Clin Invest 2007 117 12 3900 3908
68. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF, J Clin Invest 1999 104 25 R31
69. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Kennedy MA, Barrera GC, Nakamura K, Baldán A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA, Cell Metab 2005 1 121 131
70. Down regulation of cardiac renalase expression in CKD and protective effect of renalase in acute coronary syndrome. Deair G, Li Y, Liu D, J Am Soc Nephrol 2007 18 149A
71. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. Desir GV, Curr Opin Nephrol Hypertens 2008 17 2 181 185
72. Renalase, hypertension, and kidney-the discussion continues. Malyszko J, Malyszko JS, Rysz J, Mysliwiec M, Tesar V, Levin-Iaina N, Banach M, Angiology 2013 64 3 181 187
73. Hypertension and kidney disease: is renalase a new player or an innocent bystander? Malyszko J, Malyszko JS, Mikhailidis DP, Rysz J, Zorawski M, Banach M, J Hypertens 2012 30 3 457 462
74. Renalase deficiency aggravates ischemic myocardial damage. Wu Y, Xu J, Velazquez H, Wang P, Li G, Liu D, Sampaio-Maia B, Quelhas-Santos J, Russell K, Russell R, Flavell RA, Pestana M, Giordano F, Desir GV, Kidney Int 2011 79 8 853 860
75. Renalase is a novel soluble monoamine oxidase that regulates cardiac function and blood pressure. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, Wu Y, Peixoto A, Crowley S, Desir GV, J Clin Invest 2005 115 1275 1280
76. Letter on 'sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidney'. Malyszko J, Koc-Zorawska E, Banach M, Mysliwiec M, J Hypertens 2013 31 6 1272 1273
77. Pathophysiology of vascular calcification in chronic kidney disease. Moe SM, Chen NX, Circ Res 2004 95 560 567
78. Regulation of vascular calcification: roles of phosphate and osteopontin. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H, Circ Res 2005 96 717 722
79. Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Franczyk-Skóra B, Gluba A, Banach M, Rysz J, Arch Med Sci 2013 9 6 1019 1027
80. Association of serum fetuin-A with valvular calcium concentration in rheumatic mitral valve disease. Cagli K, Basar N, Cagli K, Armutcu F, Aylak F, Yalcinkaya A, Erden G, Kadirogullari E, J Heart Valve Dis 2010 19 5 636 643
81. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Yilmaz N, Arch Med Sci 2012 8 1 138 153
82. Calcium-phosphate metabolism parameters and erythrocyte Ca(2+) concentration in autosomal dominant polycystic kidney disease patients with normal renal function. Pietrzak-Nowacka M, Safranow K, Bober J, Olszewska M, Birkenfeld B, Nowosiad M, Ciechanowski K, Arch Med Sci 2013 9 5 837 842